AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 19767063 — intervention group
Group type: EXPERIMENTAL
Intervention: Debulking status
Number of subjects: 56
Study 19767063 — intervention group
Group type: EXPERIMENTAL
Intervention: VEGF expression
Number of subjects: 56
Study 19767063 — intervention group
Group type: EXPERIMENTAL
Intervention: Disease progression risk per unit increase in ΔNp63α
Number of subjects: 56
Study 19767063 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall survival (OS)
Number of subjects: 56
Study 17474134 — intervention group
Group type: EXPERIMENTAL
Intervention: HAART + CsA
Number of subjects: 15
Study 17474134 — intervention group
Group type: COMPARATOR
Intervention: HAART
Number of subjects: 15
Study 15141405 — intervention group
Group type: EXPERIMENTAL
Intervention: SMOF (alpha‐tocopherol‐enriched emulsion incorporating soybean, coconut, olive, and fish oils)
Number of subjects: 20
Study 15141405 — intervention group
Group type: COMPARATOR
Intervention: LIPOVEN (soybean oil‐based emulsion)
Number of subjects: 20
Study 11456079 — intervention group
Group type: EXPERIMENTAL
Intervention: Expert System (ES) intervention
Number of subjects: 4144
Study 11456079 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 4144
Study 9565419 — intervention group
Group type: EXPERIMENTAL
Intervention: Venipuncture (VP)
Number of subjects: 120
Study 9565419 — intervention group
Group type: COMPARATOR
Intervention: Heel-lance with small lancet (SL)
Number of subjects: 120
Study 9565419 — intervention group
Group type: COMPARATOR
Intervention: Heel-lance with large lancet (LL)
Number of subjects: 120
Study 7887116 — intervention group
Group type: EXPERIMENTAL
Intervention: Vecuronium
Number of subjects: 36
Study 7887116 — intervention group
Group type: EXPERIMENTAL
Intervention: Pancuronium
Number of subjects: 36
Study 7887116 — intervention group
Group type: COMPARATOR
Intervention: Alfentanil combined with vecuronium or pancuronium
Number of subjects: 36
Study 3060151 — intervention group
Group type: EXPERIMENTAL
Intervention: Betamethasone-dixyrazine
Number of subjects: 62
Study 3060151 — intervention group
Group type: COMPARATOR
Intervention: Metoclopramide
Number of subjects: 62
Study 3060151 — intervention group
Group type: EXPERIMENTAL
Intervention: Betamethasone-dixyrazine (with doxorubicin)
Number of subjects: 62
Study 3060151 — intervention group
Group type: COMPARATOR
Intervention: Metoclopramide (with doxorubicin)
Number of subjects: 62
Study 3060151 — intervention group
Group type: EXPERIMENTAL
Intervention: Betamethasone-dixyrazine (with cisplatin)
Number of subjects: 62
Study 3060151 — intervention group
Group type: COMPARATOR
Intervention: Metoclopramide (with cisplatin)
Number of subjects: 62
Study 3060151 — intervention group
Group type: COMPARATOR
Intervention: Metoclopramide (high-dose)
Number of subjects: 62
Study 31197894 — intervention group
Group type: EXPERIMENTAL
Intervention: Daylight PDT with curettage (standard treatment)
Number of subjects: 25
Study 31197894 — intervention group
Group type: COMPARATOR
Intervention: Daylight PDT without curettage (1 hour MAL incubation)
Number of subjects: 25
Study 31197894 — intervention group
Group type: EXPERIMENTAL
Intervention: Daylight PDT with curettage
Number of subjects: 25
Study 31197894 — intervention group
Group type: COMPARATOR
Intervention: Daylight PDT without curettage
Number of subjects: 25
Study 28186099 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention schools with redesigned play environments to encourage imaginative and independent free play by increasing opportunities for risk and challenge.
Number of subjects: 840
Study 28186099 — intervention group
Group type: COMPARATOR
Intervention: Control schools that did not change their play environment.
Number of subjects: 840
Study 26004075 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical citicoline (OMK1®, Omikron Italia, 3 drops/day) over a 4-month period
Number of subjects: 56
Study 26004075 — intervention group
Group type: COMPARATOR
Intervention: Beta-blocker monotherapy
Number of subjects: 56
Study 23084029 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination Z (oxygenated alcoholic beverage and oxygenated water)
Number of subjects: 15
Study 23084029 — intervention group
Group type: COMPARATOR
Intervention: Combination X (normal alcoholic beverage and normal water)
Number of subjects: 15
Study 23084029 — intervention group
Group type: COMPARATOR
Intervention: Combination Y (oxygenated alcoholic beverage and normal water)
Number of subjects: 15
Study 21784297 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication switch (SSRI or venlafaxine) with cognitive-behavioral therapy
Number of subjects: 334
Study 19695543 — intervention group
Group type: EXPERIMENTAL
Intervention: Bivalirudin monotherapy
Number of subjects: 2469
Study 19695543 — intervention group
Group type: COMPARATOR
Intervention: Heparin plus a GPI
Number of subjects: 2469
Study 16542287 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol +/‐ isosorbide mononitrate
Number of subjects: 71
Study 16542287 — intervention group
Group type: COMPARATOR
Intervention: Nonresponders (no pharmacological therapy)
Number of subjects: 71
Study 16542287 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduction of HVPG
Number of subjects: 71
Study 16542287 — intervention group
Group type: COMPARATOR
Intervention: No significant intervention
Number of subjects: 71
Study 15584791 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive aspects of caregiving (caregiving benefit)
Number of subjects: 217
Study 15584791 — intervention group
Group type: COMPARATOR
Intervention: Control for caregiver demographic characteristics, contextual factors, and caregiving burden
Number of subjects: 217
Study 11360771 — intervention group
Group type: EXPERIMENTAL
Intervention: Centripetal buildup technique with transparent matrices and reflective wedges
Number of subjects: 0
Study 11360771 — intervention group
Group type: COMPARATOR
Intervention: Incremental technique (not explicitly detailed in the abstract)
Number of subjects: 0
Study 9438229 — intervention group
Group type: EXPERIMENTAL
Intervention: Reboxetine (NARI)
Number of subjects: 381
Study 9438229 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine (SSRI)
Number of subjects: 381
Study 9438229 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 381
Study 8342757 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent bolus injection (Group B, n = 10)
Number of subjects: 20
Study 8342757 — intervention group
Group type: COMPARATOR
Intervention: Patient controlled administration with continuous infusion (Group P, n = 10)
Number of subjects: 20
Study 3717846 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonic therapy
Number of subjects: 120
Study 3717846 — intervention group
Group type: EXPERIMENTAL
Intervention: Shortwave diathermy
Number of subjects: 120
Study 3717846 — intervention group
Group type: EXPERIMENTAL
Intervention: Muscle relaxant drugs
Number of subjects: 120
Study 28825352 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous lidocaine plus 5% lidocaine cream (treatment group)
Number of subjects: 104
Study 28825352 — intervention group
Group type: COMPARATOR
Intervention: 1 mL of 1% lidocaine subcutaneously (control group)
Number of subjects: 104
Study 28825352 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 104
Study 28825352 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment group
Number of subjects: 104
Study 27940715 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous Bilirubinometry (TcB)
Number of subjects: 430
Study 24695080 — intervention group
Group type: EXPERIMENTAL
Intervention: Supraglottic airway training (SGA group)
Number of subjects: 23
Study 24695080 — intervention group
Group type: EXPERIMENTAL
Intervention: Cricothyroidotomy training (CRIC group)
Number of subjects: 23
Study 24695080 — intervention group
Group type: COMPARATOR
Intervention: Final test response times (CRIC group)
Number of subjects: 23
Study 24695080 — intervention group
Group type: COMPARATOR
Intervention: Final test response times (SGA group)
Number of subjects: 23
Study 22187440 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-selected ECGs
Number of subjects: 0
Study 22187440 — intervention group
Group type: COMPARATOR
Intervention: Manual-selected ECGs
Number of subjects: 0
Study 20441723 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram (20 mg to 50 mg/d)
Number of subjects: 65
Study 20441723 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 65
Study 18583190 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative chemoradiation (three cycles of cisplatin and etoposide, followed by twice-daily radiation with concurrent carboplatin and vindesine)
Number of subjects: 524
Study 18583190 — intervention group
Group type: COMPARATOR
Intervention: Control group (three cycles of cisplatin and etoposide, followed by surgery, then further radiotherapy)
Number of subjects: 524
Study 18583190 — intervention group
Group type: EXPERIMENTAL
Intervention: Pneumonectomy in interventional group
Number of subjects: 524
Study 18583190 — intervention group
Group type: COMPARATOR
Intervention: Pneumonectomy in control group
Number of subjects: 524
Study 18583190 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall survival (OS) and progression-free survival (PFS)
Number of subjects: 524
Study 15964176 — intervention group
Group type: EXPERIMENTAL
Intervention: Atypical antipsychotic drugs (n = 32)
Number of subjects: 126
Study 15964176 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional antipsychotic drugs (n = 36)
Number of subjects: 126
Study 15964176 — intervention group
Group type: EXPERIMENTAL
Intervention: Antipsychotic treatment (n = 68 responders)
Number of subjects: 126
Study 15964176 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonresponders (n = 29)
Number of subjects: 126
Study 15964176 — intervention group
Group type: COMPARATOR
Intervention: Healthy control subjects (n = 59)
Number of subjects: 126
Study 12025523 — intervention group
Group type: EXPERIMENTAL
Intervention: Psoas compartment block
Number of subjects: 60
Study 12025523 — intervention group
Group type: COMPARATOR
Intervention: Inguinal paravascular block
Number of subjects: 60
Study 10949771 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 8956204 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg oral formulation of melatonin
Number of subjects: 16
Study 8956204 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 1416895 — intervention group
Group type: EXPERIMENTAL
Intervention: sulbactam-ampicillin (4 doses of 3 g ampicillin and 1.5 g sulbactam i.v. every 6 h)
Number of subjects: 99
Study 1416895 — intervention group
Group type: COMPARATOR
Intervention: clindamycin-amikacin (4 doses of 600 mg clindamycin i.v. every 6 h and 2 doses of 500 mg amikacin i.v. every 12 h)
Number of subjects: 99
Study 3858547 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostaglandin E2 (PGE2) 3 mg/day orally for four days
Number of subjects: 8
Study 3858547 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 3858547 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostaglandin E2 (PGE2)
Number of subjects: 8
Study 29781659 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended nicotine deprivation (12‐24 hr smoking abstinence)
Number of subjects: 165
Study 29781659 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimal deprivation (2 hr smoking abstinence)
Number of subjects: 165
Study 29781659 — intervention group
Group type: COMPARATOR
Intervention: Continued smoking conditions
Number of subjects: 165
Study 27257167 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP) injection
Number of subjects: 24
Study 27257167 — intervention group
Group type: COMPARATOR
Intervention: Saline injection (placebo)
Number of subjects: 24
Study 24378880 — intervention group
Group type: EXPERIMENTAL
Intervention: Group-based acceptance and commitment therapy (GACT)
Number of subjects: 156
Study 24378880 — intervention group
Group type: COMPARATOR
Intervention: Recommended pharmacological treatment (RPT; pregabalin + duloxetine)
Number of subjects: 156
Study 24378880 — intervention group
Group type: COMPARATOR
Intervention: Wait list (WL)
Number of subjects: 156
Study 21646049 — intervention group
Group type: EXPERIMENTAL
Intervention: Mathieu repair with prepuce preservation (group I, n = 100)
Number of subjects: 200
Study 21646049 — intervention group
Group type: COMPARATOR
Intervention: Traditional Mathieu repair with circumcision (group II, n = 100)
Number of subjects: 200
Study 19695004 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduction in leg pain
Number of subjects: 100
Study 19695004 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional ability measured by Oswestry disability index (ODI)
Number of subjects: 100
Study 19695004 — intervention group
Group type: EXPERIMENTAL
Intervention: Changes in leg pain over time
Number of subjects: 100
Study 19278084 — intervention group
Group type: EXPERIMENTAL
Intervention: Oscillating/rotating power toothbrush (Oral-B Triumph Professional Care 9000)
Number of subjects: 25
Study 19278084 — intervention group
Group type: COMPARATOR
Intervention: Ultrasonic toothbrush (Ultreo)
Number of subjects: 25
Study 15992696 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic surgery
Number of subjects: 1248
Study 15992696 — intervention group
Group type: COMPARATOR
Intervention: Open surgery
Number of subjects: 1248
Study 12777959 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin-converting enzyme inhibitors
Number of subjects: 102
Study 12777959 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin receptor blockers
Number of subjects: 102
Study 12777959 — intervention group
Group type: COMPARATOR
Intervention: Calcium channel blockers
Number of subjects: 102
Study 12777959 — intervention group
Group type: COMPARATOR
Intervention: Beta blockers
Number of subjects: 102
Study 12777959 — intervention group
Group type: COMPARATOR
Intervention: Alpha receptor blockers
Number of subjects: 102
Study 11783183 — intervention group
Group type: EXPERIMENTAL
Intervention: Tangshen Mixture (TSM) + insulin
Number of subjects: 93
Study 11783183 — intervention group
Group type: COMPARATOR
Intervention: Insulin alone (Control)
Number of subjects: 93
Study 8904352 — intervention group
Group type: EXPERIMENTAL
Intervention: Dideuterated glucose as tracer, with non-adapted tracer priming dose
Number of subjects: 10
Study 8904352 — intervention group
Group type: EXPERIMENTAL
Intervention: Dideuterated glucose as tracer, with appropriately matched priming dose
Number of subjects: 10
Study 8904352 — intervention group
Group type: COMPARATOR
Intervention: NIDDM patients
Number of subjects: 10
Study 31757518 — intervention group
Group type: EXPERIMENTAL
Intervention: d-amphetamine (20 mg)
Number of subjects: 73
Study 31757518 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 73
Study 31373919 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiretroviral treatment (ART) discontinuation
Number of subjects: 1076
Study 31373919 — intervention group
Group type: COMPARATOR
Intervention: ACTG treatment interruption trials (historical control, 91% male population)
Number of subjects: 1076
Study 28863364 — intervention group
Group type: EXPERIMENTAL
Intervention: WBdiet (42 g total protein, 28 g whey, n=19)
Number of subjects: 56
Study 28863364 — intervention group
Group type: EXPERIMENTAL
Intervention: PBdiet (42 g various protein sources, n=19)
Number of subjects: 56
Study 28863364 — intervention group
Group type: COMPARATOR
Intervention: CBdiet (high‐carbohydrate breakfast, 17 g protein from various sources, n=18)
Number of subjects: 56
Study 27089862 — intervention group
Group type: EXPERIMENTAL
Intervention: lopinavir/ritonavir (LPV/r)
Number of subjects: 33
Study 27089862 — intervention group
Group type: COMPARATOR
Intervention: efavirenz (EFV)
Number of subjects: 33
Study 24471907 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirabegron 50 mg once daily
Number of subjects: 1139
Study 24471907 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1139
Study 22222224 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol 25mg and Meloxicam 7.5mg
Number of subjects: 51
Study 22222224 — intervention group
Group type: EXPERIMENTAL
Intervention: Meloxicam 15mg
Number of subjects: 51
Study 22222224 — intervention group
Group type: COMPARATOR
Intervention: Tramadol 50mg
Number of subjects: 51
Study 18401549 — intervention group
Group type: EXPERIMENTAL
Intervention: Glyceryl trinitrate (GTN) 0.5 microg/kg/min i.v. for 20 min
Number of subjects: 6
Study 16157010 — intervention group
Group type: EXPERIMENTAL
Intervention: COX‐2 inhibitor therapy (Rofecoxib) 25 mg/day for 10 days before surgery
Number of subjects: 50
Study 12825134 — intervention group
Group type: EXPERIMENTAL
Intervention: UDCA at 600 mg/day plus bezafibrate at 400 mg/day
Number of subjects: 22
Study 12825134 — intervention group
Group type: COMPARATOR
Intervention: UDCA at 600 mg/day (control group)
Number of subjects: 22
Study 10971229 — intervention group
Group type: EXPERIMENTAL
Intervention: USA UDCA tablet
Number of subjects: 24
Study 10971229 — intervention group
Group type: EXPERIMENTAL
Intervention: Canadian UDCA tablet
Number of subjects: 24
Study 10971229 — intervention group
Group type: EXPERIMENTAL
Intervention: Ursolvan capsules
Number of subjects: 24
Study 10971229 — intervention group
Group type: EXPERIMENTAL
Intervention: Actigall capsules
Number of subjects: 24
Study 10971229 — intervention group
Group type: EXPERIMENTAL
Intervention: Canadian UDCA tablet (dose proportionality)
Number of subjects: 24
Study 10971229 — intervention group
Group type: EXPERIMENTAL
Intervention: North American tablets
Number of subjects: 24
Study 8795318 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 ml of 0.25% bupivacaine plain solution
Number of subjects: 10
Study 8795318 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 ml of 0.25% bupivacaine plain solution
Number of subjects: 10
Study 1458939 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopamine infusion > 5 micrograms/kg/min for 4 hrs
Number of subjects: 0
Study 1458939 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopamine infusion
Number of subjects: 0
Study 1458939 — intervention group
Group type: COMPARATOR
Intervention: Control group (ICU patients not receiving dopamine)
Number of subjects: 0
Study 2580183 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril (53 mg/day) + Calcium antagonist (verapamil 500 mg/day or nitrendipine 70 mg/day)
Number of subjects: 16
Study 2580183 — intervention group
Group type: COMPARATOR
Intervention: Captopril (84 mg/day) + Diuretic
Number of subjects: 16
Study 30892700 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemoendocrine therapy (NCET)
Number of subjects: 249
Study 30892700 — intervention group
Group type: COMPARATOR
Intervention: Neoadjuvant chemotherapy (NCT)
Number of subjects: 249
Study 30269241 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth mindset (33 patients: 17 epidural, 16 PCA)
Number of subjects: 50
Study 30269241 — intervention group
Group type: COMPARATOR
Intervention: Fixed mindset (17 patients: 8 epidural, 9 PCA)
Number of subjects: 50
Study 27380504 — intervention group
Group type: COMPARATOR
Intervention: Triple therapy (α‐blocker, anti‐inflammatory agent, muscle relaxant)
Number of subjects: 60
Study 27380504 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined extracorporeal shock-wave therapy (ESWT) and triple therapy
Number of subjects: 60
Study 22351381 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamotrigine 100 mg/day
Number of subjects: 33
Study 22351381 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study 20538187 — intervention group
Group type: EXPERIMENTAL
Intervention: NGX‐4010, a high‐concentration capsaicin patch (capsaicin 8%)
Number of subjects: 106
Study 18540853 — intervention group
Group type: EXPERIMENTAL
Intervention: High-quality randomized controlled trials
Number of subjects: 0
Study 18540853 — intervention group
Group type: EXPERIMENTAL
Intervention: Systematic reviews and meta-analyses
Number of subjects: 0
Study 16148470 — intervention group
Group type: EXPERIMENTAL
Intervention: SOFA scoring by ICU physicians
Number of subjects: 30
Study 14580927 — intervention group
Group type: COMPARATOR
Intervention: Placebo (T0)
Number of subjects: 53
Study 14580927 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of inhaled salmeterol (50 microg) (T1)
Number of subjects: 53
Study 14580927 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular treatment with inhaled salmeterol (50 microg bid) for 1 week (T2)
Number of subjects: 53
Study 10544919 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral lefradafiban (the oral prodrug of fradafiban)
Number of subjects: 8
Study 10544919 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 8703282 — intervention group
Group type: EXPERIMENTAL
Intervention: Skill training strategy (30 minutes session)
Number of subjects: 53
Study 8703282 — intervention group
Group type: COMPARATOR
Intervention: Insight training strategy (30 minutes session)
Number of subjects: 53
Study 1898951 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate angioplasty
Number of subjects: 291
Study 1898951 — intervention group
Group type: COMPARATOR
Intervention: Noninvasive treatment (rt-PA, aspirin, heparin without angioplasty)
Number of subjects: 291
Study 1898951 — intervention group
Group type: COMPARATOR
Intervention: Noninvasive treatment
Number of subjects: 291
Study 6194145 — intervention group
Group type: EXPERIMENTAL
Intervention: Acyclovir (5 mg/kg)
Number of subjects: 16
Study 6194145 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 29391372 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal saline instillation
Number of subjects: 0
Study 29391372 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung recruitment
Number of subjects: 0
Study 29391372 — intervention group
Group type: COMPARATOR
Intervention: No normal saline instillation
Number of subjects: 0
Study 29391372 — intervention group
Group type: COMPARATOR
Intervention: No lung recruitment
Number of subjects: 0
Study 26192160 — intervention group
Group type: EXPERIMENTAL
Intervention: Reappraisal
Number of subjects: 137
Study 26192160 — intervention group
Group type: EXPERIMENTAL
Intervention: Distraction
Number of subjects: 137
Study 26192160 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 137
Study 25545673 — intervention group
Group type: EXPERIMENTAL
Intervention: mesalamine
Number of subjects: 33
Study 22781891 — intervention group
Group type: EXPERIMENTAL
Intervention: Procalcitonin (PCT) measurement
Number of subjects: 103
Study 20459846 — intervention group
Group type: EXPERIMENTAL
Intervention: MoleMate system plus best practice
Number of subjects: 0
Study 20459846 — intervention group
Group type: COMPARATOR
Intervention: Best practice alone
Number of subjects: 0
Study 18669787 — intervention group
Group type: EXPERIMENTAL
Intervention: Heated humidification
Number of subjects: 16